Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Rivaroxaban Sandoz 15 mg Film-coated Tablets

Active Ingredient:
rivaroxaban
Company:  
Sandoz Limited See contact details
ATC code: 
B01AF01
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Risk Materials Letters to HCPs
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

Letter to HCPs

{healthcare_pro_orange} For Healthcare Professionals
The British Generics Medicines Association (BGMA) on behalf of Sandoz and other Marketing authorisation holders for the product Rivaroxaban have distributed this prescriber letter intended to minimise the risk of treatment of Rivaroxaban. This prescriber letter was posted ( hard copy) to a total of 81,963 healthcare professionals in May 2024. This is a copy of the letter that was distributed upon launch of this product.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Sandoz Limited
Company image
Address
Maxis 1, Western Road, Bracknell, RG12 1RF, UK
WWW
http://www.sandoz.uk.com
WWW
https://pvi1j.solutions.iqvia.com
Telephone
+44 (0) 1276 698020
Medical Information Direct Line
+44 (0)1276 698 101
Medical Information e-mail
[email protected]
Adverse event reporting email
[email protected]
Customer Care direct line
+44 (0)1276 698020
E-mail
[email protected]
E-mail
[email protected]